Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai

🌈🌈Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai! 🌟🌟 #CARTVictory

⚡️⚡️Lyn, a mother of three from Singapore, faced unexpected health challenges in 2022. She experienced persistent pain in her shoulders, neck, and upper limbs, disrupting her sleep and even affecting her ability to breathe. A visit to the emergency department at Shanghai Jiahui International Hospital revealed a shocking discovery – a massive tumor in her mediastinum, measuring 15 cm in diameter! The compression from this large mass not only caused excruciating pain but also impacted nearby organs such as the heart, major blood vessels, and lungs, leading to Superior Vena Cava Syndrome (SVCS). Lyn struggled with breathing difficulties, posing an imminent threat to her life.

🌸🌸The diagnosis pointed to “Primary Mediastinal Large B-cell Lymphoma,” a relatively uncommon subtype of lymphoma, prevalent among young individuals, particularly females. Despite undergoing various comprehensive treatments, including chemotherapy combined with targeted therapy and consolidative radiotherapy, Lyn unfortunately showed no response to these treatments. Eventually, the decision was made to pursue CAR-T cell therapy.

🧶🧶Lyn’s husband emphasized, “The cost of CAR-T treatment abroad is significantly higher than in China, and the waiting period is at least 3-6 months. We trust the medical expertise of China and Shanghai Jiahui. Their professionalism and meticulous care left a deep impression on us. Our decision was absolutely correct.”

💥💥 The treatment team at Shanghai Jiahui International Hospital, led by Director Vicky H. Lee and Dr. Lili Zhou, the head of the Hematology and Oncology Department, developed a meticulous treatment plan to navigate Lyn through the entire CAR-T therapy. They highlighted the critical importance of two stages: the period from cell collection to pre-infusion and the phase post-infusion, which poses a risk of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

🍁🍁 After careful preliminary treatments, infection screening, and confirmation through cell collection, Lyn received the CAR-T cell infusion. Following infusion, the “T-cell soldiers” proliferated successfully in her body, providing relief from tumor-related pain. Upon clinical assessment confirming stable conditions, Lyn smoothly transitioned to being discharged.

⛵️⛵️ It’s worth noting that CAR-T therapy costs comprise drug and non-drug expenses, with the overall treatment expenses significantly lower in China compared to Western countries. Shanghai Jiahui International Hospital collaborates with local high-quality medical resources such as Ruijin Hospital and Tongji Hospital, offering patients a comprehensive one-stop CAR-T diagnostic and therapeutic service.

#CART #SurvivorStories #MedicalMiracle #Inspiration #JiahuiInternationalHospital #CancerSurvivor #CARTTherapy #HealthJourney #advancedmedicineinchina #chinesemedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy

🌟2024 Lancet:  Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy 🌏

LANCET

 

Dive into the cutting-edge world of CAR T-cell therapy, where China is making waves in the realm of cellular treatments. Since the inception of CAR T-cell clinical trials in 2013, this groundbreaking therapy has become a beacon of hope for cancer patients across the country.

🔬 Explosive Growth: By 2017, China led the globe in the number of CAR T-cell-related clinical trials, marking a pivotal moment in the evolution of cancer treatments. Fast forward to 2021, and Chinese cell therapy companies have amassed a staggering $237 million in funding, reflecting the robust expansion of CAR T-cell therapy in the nation.

🌐 Government Support: A deep dive into the research unveils the influential role of Chinese government policies in propelling CAR T-cell therapy forward. Strong governmental backing, coupled with capital influx, massive patient demand, and a unique healthcare system, lays the foundation for the accelerated growth of this revolutionary therapy in China.

🎗️ Overcoming Challenges: While CAR T-cell therapy is still in its infancy for solid tumors, it has achieved remarkable success in treating blood cancers. China has emerged as a global leader in conducting clinical trials, particularly focusing on hematologic malignancies like B-cell lymphomas. CAR-T cells, reprogrammed to combat cancer, offer a beacon of hope for those facing these formidable diseases.

🚀 Pushing Boundaries: Beyond blood cancers, Chinese researchers are actively exploring the potential of CAR-T cell therapy in various solid tumors. Preliminary studies hint at promising results for liver, pancreatic, and brain cancers. China’s commitment to medical innovation shines through as it pushes the boundaries of cancer research and treatment strategies.

🌈 Hope for the Future: Join us in celebrating the strides China is making in cancer research. Every breakthrough in CAR T-cell therapy brings us closer to a future where cancer is not just treated but conquered.

💪🏼🔬 #CARTCellChina #MedicalInnovation #CancerBreakthrough #HopeForTheFuture #GlobalHealthRevolution #CellTherapy #LANCET #HEMATOLOGY